Cosciens Biopharma reports Q3 revenue $1.9M vs $2M last year

“We have conducted a thorough evaluation and prioritization of our combined pipeline of products and programs. This evaluation focused on prioritizing programs and products in the nutraceutical and cosmeceutical space and critically assessing the required investment and timelines for our pharmaceutical projects to reach key value inflection points. We are pleased with the continued progress in our Phase 1/2a clinical trial of our Avenanthramide product being developed as a potential anti-inflammatory. We remain on track to complete enrollment of the Phase 1 component by the end of 2024 and expect to complete enrollment in the Phase 2a component by Q3 2025. In contrast, the projected timelines and costs to reach the next value inflection point in the pre-clinical auto-immune modifying disease (“AIMS Biologicals”) platform and Delayed Clearance Parathyroid Hormone (“DC-PTH”, AEZS-150) fusion proteins program are increasingly challenging and, as a result, we have made the decision to discontinue further investment in these programs,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of COSCIENS.